VLST Corp Names Consuelo M. Blosch, M.D., Vice President of Clinical and Regulatory and Dan Allison, Ph.D., Sr. Director of Therapeutic Design

Sep 17, 2007, 01:00 ET from VLST Corporation

    SEATTLE, Sept. 17 /PRNewswire/ -- VLST Corp, a Seattle-based
 biotechnology company focused on the development of therapeutics for
 autoimmune and inflammatory disorders, today announced the appointments of
 Consuelo M. Blosch, M.D. as Vice President of Clinical and Regulatory and
 Dan Allison, Ph.D, as Senior Director of Therapeutic Design.
     Blosch joins VLST from the Benaroya Research Institute at Virginia
 Mason (BRI), where she served as administrative director of the BRI
 Clinical Research Program. There, she provided leadership oversight to
 investigators involved in more than 200 clinical trials. Prior to BRI,
 Blosch held director level positions at Immunex Corporation and NPS
 Pharmaceuticals, Inc. At Immunex, where she worked from 1992 to 1998,
 Blosch directed the soluble receptor program, participating in the study
 design and overseeing the monitoring for clinical trials including those
 for ENBREL. At NPS, she directed a global research program for a
 recombinant human parathyroid hormone for the treatment of osteoporosis.
 Blosch received an M.D. from the University of Massachusetts Medical
     Allison joins VLST from ICOS Corporation, where he worked from 1992 to
 2007, and most recently served as Senior Director, Production Development.
 At ICOS, Allison was responsible for engineering antibodies and other
 proteins used in clinical studies and also directed the development of
 microbial and mammalian expression systems used to produce those proteins.
 Prior to ICOS, Allison worked at Genencor International. Allison received a
 Ph.D. from the Genetics Department at the University of Washington and
 carried out post- doctoral studies in yeast cell biology at the Biozentrum
 in Basel, Switzerland and in the Biochemistry Department at the University
 of Washington.
     "Consuelo's vast experience in the implementation, direction and design
 of clinical trials will be truly invaluable to VLST as we begin to advance
 our novel product candidates toward clinical development," said Martin
 Simonetti, President and Chief Executive Officer of VLST. "In addition, Dan
 brings significant protein engineering expertise that will guide the design
 of our therapeutic candidates. We are pleased to have such talented
 individuals join our team and look forward to their contributions."
     About VLST
     VLST Corporation is a privately held biotechnology company dedicated to
 the streamlined discovery and development of novel therapeutics for the
 treatment of inflammatory and autoimmune disorders. The VLST approach
 combines novel bioinformatics and cutting-edge proteomics to provide a
 rapid and rational approach to identifying new targets for the development
 of novel biologic therapies. The process used to identify clinically
 relevant targets also provides a path to developing biologic molecules that
 can be used for target validation studies. Such an approach offers the
 opportunity to improve the prioritization of product candidates and reduce
 costs by improving the clinical success rate. The VLST discovery platform
 has primary applications for the treatment of rheumatoid arthritis, Crohn's
 disease, multiple sclerosis, lupus and diabetes. For more information,
 please visit http://www.vlstcorp.com.

SOURCE VLST Corporation